About ETHA

The European Thrombosis and Haemostasis Alliance (ETHA) is comprised of eminent clinicians and researchers from European national and international societies representing those working in the field of thrombotic and bleeding disorders. ETHA has come together to give the European thrombosis and haemostasis community an allied voice and provide input to EU health and patient safety strategies; make recommendations on EU research programme funding and encourage sharing and adoption of best practices in the treatment and prevention of thrombotic and bleeding disorders across Member States.

Thrombosis & Haemostasis

Coagulation disorders (thrombosis and haemostasis) are disruptions in the body’s ability to control blood clotting. Coagulation disorders can result in either a hemorrhage (too little clotting that causes an increased risk of bleeding) or thrombosis (too much clotting that causes blood clots to obstruct blood flow). More specifically, thrombosis is the formation of potentially deadly blood clots in an artery or vein. It is the underlying cause of heart attack, thromboembolic stroke, and venous thromboembolism (VTE), the top three cardiovascular killers. Haemostasis is the human body's response to blood vessel injury and bleeding. It involves a coordinated effort between platelets and numerous blood clotting proteins (or factors), resulting in the formation of a blood clot and subsequent stopping of the bleed.

European Thrombosis & Haemostasis Alliance Consensus Statement

Using the upcoming Framework Programme 9 to make Europe a world leader in thrombosis and haemostasis research for the benefit of patients in Europe and beyond

The European Thrombosis and Haemostasis Alliance (ETHA) calls on the European Commission, the European Parliament and the Council of the European Union to adopt an ambitious Framework Programme 9 that emphasizes and supports funding for medical research, to advance the understanding, prevention, diagnosis and treatment of bleeding and clotting disorders. As an alliance representing 21 European Member State Thrombosis and Haemostasis scientific associations, we firmly believe that Europe can continue and even strengthen its role as a global leader in the field of science and medical R&D. It is vital that Europe continues its investment in health research by formulating a forward-looking research agenda in the Framework Programme 9 that addresses the challenges and effects of chronic disease and an ageing European population.